Trials / Terminated
TerminatedNCT00505648
Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)
Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University Hospital, Rouen · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and tolerance of Tegeline® treatment in hypersensitivity syndrome. Immunological study of the T cell index phenotype and functionality in hypersensitivity syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegeline® | 2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2007-07-23
- Last updated
- 2015-03-24
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00505648. Inclusion in this directory is not an endorsement.